XML 28 R17.htm IDEA: XBRL DOCUMENT v3.26.3
Subsequent Events
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events
9.
Subsequent Events

 

Shares issued for Services

 

Subsequent to September 30, 2026, the Company issued an aggregate of 116,103 shares of its common stock, par value $0.001 per share, to members of the Board of Directors, consultants and an employee in consideration for board service fees, services rendered and salary compensation, respectively, with an aggregate fair value of approximately $86.

 

Asset Acquisition

On October 13, 2026, the Company acquired Velaris Therapeutics, Inc., a Delaware corporation (“Pre-Acquisition Velaris”), in accordance with the terms of the Agreement and Plan of Merger, dated October 13, 2026 (the “Acquisition Agreement”), by and among the Company, Valkyrie Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), Valkyrie Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Pre-Acquisition Velaris. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Pre-Acquisition Velaris, pursuant to which Pre-Acquisition Velariswas the surviving corporation and became a wholly owned subsidiary of the Company (the “First Merger”). Immediately following the First Merger, Pre-Acquisition Velaris merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity (together with the First Merger, the “Asset Acquisition”). The Asset Acquisition is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Under the terms of the Acquisition Agreement, following the closing of the Asset Acquisition (the “Closing”), the Company issued to the stockholders of Pre-Acquisition Velaris (i) 105,286 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) and (ii) 33,054 shares of Series C Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), each share of which is, in each case, convertible into 1,000 shares of common stock of the Company, subject to certain conditions. In addition, shares of Series C Preferred Stock issued in respect of outstanding unvested restricted shares of Velaris common stock remain subject to the same vesting terms, and each outstanding option to purchase shares of Velaris common stock was assumed by the Company and converted into an option to purchase shares of common stock, with the number of shares and exercise price adjusted based on the exchange ratio in the Merger Agreement. Following satisfaction of the applicable conditions, Series B Preferred Stock is convertible at the holder’s option and Series C Preferred Stock converts automatically. If the required approvals are not obtained, holders may request cash settlement of conversions beginning six months after issuance, subject to applicable waivers.

 

Private Placement Financing

In connection with the Asset Acquisition, the Company also entered into a significant private investment in public equity (“PIPE”) transaction. The Company agreed to sell (i) 687,789 shares of common stock at a price of $1.4357 per share and (ii) 243,063 shares of Series C Preferred Stock at a price of $1,435.70 per share in the PIPE for approximately $350 million in gross proceeds. The PIPE closed on October 14, 2026. The Series C Preferred Stock are convertible into Common Stock at a ratio of 1,000 shares of common stock per share of Series C Preferred Stock, subject beneficial‑ownership limitations. The proceeds are intended primarily to fund development of the acquired programs and for working capital and general corporate purposes, subject to contractual restrictions on their use.

 

Related Agreements

In connection with the Asset Acquisition, the Company agreed, subject to required stockholder approval, to repurchase its outstanding Series A-1 and Series A-2 Convertible Preferred Stock, including shares of common stock issued upon conversion, from holders including certain directors and an affiliated entity. The payment, based on liquidation value and accrued dividends, is expected to be approximately $1.6 million if approval occurs before February 2027.

 

Prior to the effective time of the Asset Acquisition, Velaris entered into a Fusion Protein Discovery and Option Agreement (the “ADOA”) with Paragon Laboratories, Inc. (“Paragon”). Pursuant to the ADOA, Paragon will conduct research programs, overseen by a joint development committee of representatives of each party, directed to the discovery and development of Fc fusion protein candidates, including programs directed to ActRIIA and ActRIIB that were initiated under a prior research letter agreement between Velaris and Paragon, and a program directed to a BMP9/10-sparing ActRIIA fusion protein. The parties may agree to conduct additional research programs under the ADOA. In addition, under the research letter agreement between Velaris and Paragon, Velaris holds options with respect to three research programs directed to antibody candidates, including an anti-PDGF-B monoclonal antibody and a bispecific molecule combining an ActRIIA fusion protein with an anti-PDGF-B antibody, which the parties expect to document in a separate discovery and option agreement. The Company assumed the ADOA and the research letter agreement in connection with

the Asset Acquisition. The ADOA also provide for the issuance of two warrants to Paragon, each representing 1% of the Company’s fully diluted outstanding common stock, with grants scheduled 120 days after closing and twelve months thereafter.

 

On October 13, 2026, the Company granted two executive officers options to purchase an aggregate of 60,000 shares of common stock under its 2020 Equity Incentive Plan at an exercise price of $1.4357 per share. Of these, 50,000 vest on July 30, 2027, subject to the recipient continuing to lead development of ALN1003 through that date, and 10,000 vest upon the successful filing of both the Company’s 2026 Annual Report on Form 10-K and its Quarterly Report on Form 10-Q for the quarter ending March 31, 2027. Both awards require continued service through the applicable vesting date and expire on October 12, 2036, subject to earlier termination under the award agreements.